Delayed hypersensitivity reaction after oral intake of non-ionic iodinated contrast medium

2021 ◽  
pp. 1-2
Author(s):  
Alan A. Peters ◽  
Johannes T. Heverhagen ◽  
Ingrid B. Boehm
2019 ◽  
Vol 44 (1) ◽  
pp. 118-121 ◽  
Author(s):  
Honorio T Benzon ◽  
Jeffrey Schechtman ◽  
Sophy C Zheng ◽  
Jeffery A Katz ◽  
Arpan Patel ◽  
...  

In patients with a history of a hypersensitivity reaction to iodinated contrast medium, iodinated contrast medium is avoided, antihistamine and steroid premedication are given, or a gadolinium-based contrast agent is employed. Six patients with a history of a hypersensitivity reaction to iodinated contrast medium and who were not premedicated had an unintentional injection of iodinated contrast. None of the patients developed a moderate or severe reaction. All patients had gadopentetate dimeglumine in one of their injections; three had repeated injections of the gadopentetate. The lack of a significant reaction may be due to any or all of the following: questionable history of iodinated contrast reaction, low dose of iodinated contrast given, concomitant injection of (epidural) steroid, and slower absorption from epidural compared with intravenous injection. While it is reassuring to know that there is a low possibility of a moderate to severe reaction in these patients, every effort should be made to avoid this scenario, appropriate drugs and resuscitation equipment should be immediately available, and the patients should be observed adequately and followed for the possibility of late reactions. Recent publications have called for caution in the use of gadolinium-based contrast agents.


2003 ◽  
Vol 48 (3) ◽  
pp. 167-167 ◽  
Author(s):  
Javier Sánchez-Pérez ◽  
María García F-Villalta ◽  
Sara Alvarez Ruíz ◽  
Amaro García Diez

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Caroline Michèle Andrist ◽  
Lukas Jörg ◽  
Thomas Greuter ◽  
Anna Gschwend ◽  
Alex Straumann ◽  
...  

Abstract Background Eosinophilic esophagitis (EoE) is a chronic inflammatory disease that has been known since the early 1990s. Swallowed topical corticosteroids (STC) belong to the therapeutic cornerstones. We describe a delayed hypersensitivity reaction to Jorveza®, a newly developed orodispersible budesonide tablet licensed for the treatment of eosinophilic esophagitis. Case presentation A 32-year-old Caucasian woman with EoE was newly treated with Jorveza®. Hours after the first intake, she felt a “strange pruritus” in the throat. This sensation worsened with each subsequent intake. On day 4 she developed oral mucosal symptoms (paresthesia of the tongue, sore and an itchy throat). Intraoral, throat and facial swellings, but no systemic reaction were observed. Patch testing using two commercial test series as well as the orodispersible budesonide tablet revealed a strong sensitization, proving a T cell mediated allergy to budesonide. Conclusions Orodispersible budesonide is increasingly prescribed for the treatment of eosinophilic esophagitis. The development of oropharyngeal symptoms after initiating should alert the treating physician to the possibility of a hypersensitivity reaction.


2014 ◽  
Vol 21 (6) ◽  
pp. 474-477 ◽  
Author(s):  
Aliakbar Dadla ◽  
Susan Tannenbaum ◽  
Breton Yates ◽  
Lisa Holle

1995 ◽  
Vol 23 (5) ◽  
pp. 295-299 ◽  
Author(s):  
K. Katsuno ◽  
A. Manabe ◽  
K. Itoh ◽  
H. Hisamitsu ◽  
S. Wakumoto ◽  
...  

Radiology ◽  
2009 ◽  
Vol 253 (3) ◽  
pp. 870-878 ◽  
Author(s):  
Douglas B. Macha ◽  
Rendon C. Nelson ◽  
Laurens E. Howle ◽  
John W. Hollingsworth ◽  
Sebastian T. Schindera

Sign in / Sign up

Export Citation Format

Share Document